Found 8 matching trials
A Dose Escalation Study to Assess Safety of GSK2256098 (FAK Inhibitor) in Combination With Trametinib (MEK Inhibitor) in Subjects With Advanced Solid Tumors PHASE1 The purpose of this study is to assess the safety of combination treatment ...
Show More Location
GSK Investigational Site
Learn More & Join Trial
Trial of Safety, Tolerability and Efficacy of Trametinib (SNR1611) in Patients With Amyotrophic Lateral Sclerosis (ALS) PHASE1 The purpose of this study is to evaluate the safety, tolerability and effic...
Show More Location
Inje University Busan Paik Hospital
Learn More & Join Trial
Dabrafenib and/or Trametinib Rollover Study PHASE4 This study is to provide access for patients who are receiving treatment wi...
Show More Location
Honor Health Research Institute
Learn More & Join Trial
A Phase IIa Study of the MEK Inhibitor Trametinib Monotherapy in the Treatment of Biliary Tract Cancers PHASE2 This is a Phase IIa, open-label, single-arm, multi-center study to evaluate...
Show More Location
GSK Investigational Site
Learn More & Join Trial
A Study of PDR001 in Combination With CJM112, EGF816, Ilaris® (Canakinumab) or Mekinist® (Trametinib) PHASE1 The purpose of this study was to combine the PDR001 checkpoint inhibitor wi...
Show More Location
Sidney Kimmel Comprehensive Cancer Center SC-3
Learn More & Join Trial
Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib in Subjects With BRAF V600E- Mutated Rare Cancers PHASE2 This was a Phase II, open-label, non-randomized, multi-center study of oral...
Show More Location
Novartis Investigative Site
Learn More & Join Trial
Study of Efficacy and Safety of LXH254 Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma PHASE2 The primary purpose of this study is to evaluate the efficacy of LXH254 com...
Show More Status
Active Not Recruiting
Location
The Angeles Clinic and Research Institute
Learn More & Join Trial
Study to Investigate the Objective Response Rate of Dabrafenib in Combination With Trametinib in Subjects With BRAF V600 Mutation-Positive Melanoma PHASE2 This was a single-arm, open-label, multi-center, Phase II study to evaluate...
Show More Location
Novartis Investigative Site
Learn More & Join Trial